Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.

BACKGROUND: The Committee for Evidence-based Medicine (EBM) of the Japan Society for Oriental Medicine started compiling Evidence Reports of Kampo Treatment (EKAT) in 2007. EKAT is a compilation of structured abstracts of randomized controlled trials (RCTs), along with comments by a third party revi...

Full description

Bibliographic Details
Main Authors: Yoshiharu Motoo, Ichiro Arai, Kiichiro Tsutani
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4132104?pdf=render
id doaj-70ef25a7506949bba27b62018b6b6d5d
record_format Article
spelling doaj-70ef25a7506949bba27b62018b6b6d5d2020-11-25T01:12:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10442210.1371/journal.pone.0104422Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.Yoshiharu MotooIchiro AraiKiichiro TsutaniBACKGROUND: The Committee for Evidence-based Medicine (EBM) of the Japan Society for Oriental Medicine started compiling Evidence Reports of Kampo Treatment (EKAT) in 2007. EKAT is a compilation of structured abstracts of randomized controlled trials (RCTs), along with comments by a third party reviewer. As of 31 December, 2012, there were 378 RCTs of Kampo medicines in Japan. The primary research question of this study is "How frequently is Kampo diagnosis used in RCTs of Kampo medicines?" The secondary research question is "When is Kampo diagnosis used in RCTs?" MATERIALS AND METHODS: The structured abstract (SA) of each RCT article was reviewed to examine how Kampo diagnosis was used in RCTs, especially how Kampo diagnosis was used in the randomization process. RESULTS: Kampo diagnosis was used before randomization in 27 RCTs (7.1%), after randomization in 31 RCTs (8.2%), and not used in 320 RCTs (84.7%). Before randomization, Kampo diagnosis was used as a criterion for inclusion in 10 RCTs, criterion for exclusion in 9 RCTs, and criteria for both inclusion and exclusion in 2 RCTs. Kampo formulas were determined according to Kampo diagnosis in 7 RCTs. After randomization, subgroup analyses according to Kampo diagnosis were done in 27 RCTs, and grade of disease severity at Kampo diagnosis was used for analysis as an endpoint in 4 RCTs. CONCLUSIONS: Kampo diagnosis was used before randomization only in approximately 15% of RCTs, and the number of RCT articles using Kampo diagnosis after randomization was almost the same as that before randomization. Further studies to determine the good RCTs conforming to CONSORT requirements and good systematic reviews conforming to PRISMA requirements are needed to clarify the significance of Kampo diagnosis.http://europepmc.org/articles/PMC4132104?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Yoshiharu Motoo
Ichiro Arai
Kiichiro Tsutani
spellingShingle Yoshiharu Motoo
Ichiro Arai
Kiichiro Tsutani
Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.
PLoS ONE
author_facet Yoshiharu Motoo
Ichiro Arai
Kiichiro Tsutani
author_sort Yoshiharu Motoo
title Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.
title_short Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.
title_full Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.
title_fullStr Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.
title_full_unstemmed Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.
title_sort use of kampo diagnosis in randomized controlled trials of kampo products in japan: a systematic review.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description BACKGROUND: The Committee for Evidence-based Medicine (EBM) of the Japan Society for Oriental Medicine started compiling Evidence Reports of Kampo Treatment (EKAT) in 2007. EKAT is a compilation of structured abstracts of randomized controlled trials (RCTs), along with comments by a third party reviewer. As of 31 December, 2012, there were 378 RCTs of Kampo medicines in Japan. The primary research question of this study is "How frequently is Kampo diagnosis used in RCTs of Kampo medicines?" The secondary research question is "When is Kampo diagnosis used in RCTs?" MATERIALS AND METHODS: The structured abstract (SA) of each RCT article was reviewed to examine how Kampo diagnosis was used in RCTs, especially how Kampo diagnosis was used in the randomization process. RESULTS: Kampo diagnosis was used before randomization in 27 RCTs (7.1%), after randomization in 31 RCTs (8.2%), and not used in 320 RCTs (84.7%). Before randomization, Kampo diagnosis was used as a criterion for inclusion in 10 RCTs, criterion for exclusion in 9 RCTs, and criteria for both inclusion and exclusion in 2 RCTs. Kampo formulas were determined according to Kampo diagnosis in 7 RCTs. After randomization, subgroup analyses according to Kampo diagnosis were done in 27 RCTs, and grade of disease severity at Kampo diagnosis was used for analysis as an endpoint in 4 RCTs. CONCLUSIONS: Kampo diagnosis was used before randomization only in approximately 15% of RCTs, and the number of RCT articles using Kampo diagnosis after randomization was almost the same as that before randomization. Further studies to determine the good RCTs conforming to CONSORT requirements and good systematic reviews conforming to PRISMA requirements are needed to clarify the significance of Kampo diagnosis.
url http://europepmc.org/articles/PMC4132104?pdf=render
work_keys_str_mv AT yoshiharumotoo useofkampodiagnosisinrandomizedcontrolledtrialsofkampoproductsinjapanasystematicreview
AT ichiroarai useofkampodiagnosisinrandomizedcontrolledtrialsofkampoproductsinjapanasystematicreview
AT kiichirotsutani useofkampodiagnosisinrandomizedcontrolledtrialsofkampoproductsinjapanasystematicreview
_version_ 1725167506485673984